CONFERENCE PROGRAM AND SCHEDULE

**Wednesday, September 16, 2015**

1:30 p.m.-1:35 p.m.
**Welcome**
Metropolitan Ballroom
Jill O'Donnell-Tormey, Cancer Research Institute, New York, NY

1:35 p.m.-2:05 p.m.
**Keynote Address**
Metropolitan Ballroom
**T cells as a drug for the personalized immunotherapy of cancer**
Steven A. Rosenberg, National Cancer Institute, Bethesda, MD

2:05 p.m.-4:05 p.m.
**Plenary Session 1: Immune Regulation of T-Cell Responses/Evolving Concepts in Cancer Immunology**
Metropolitan Ballroom
**Session Chairperson:** James P. Allison, The University of Texas MD Anderson Cancer Center, Houston, TX

2:05 p.m.  **Chairperson perspective: Immune checkpoint blockade in cancer therapy: New insights, opportunities, and prospects for a cure**
James P. Allison

2:15 p.m.  **Biology of the PD-1 pathway**
Arlene H. Sharpe, Harvard Medical School, Boston, MA

2:45 p.m.  **Antitumor activity of immunomodulatory antibodies**
Alan Korman, Bristol-Myers Squibb, Redwood City, CA

3:15 p.m.  **The interplay between L-arginine metabolism and adoptive immunity in cancer**
Vincenzo Bronte, Venetian Institute of Molecular Medicine, Padova, Italy

3:45 p.m.  **Tumor-derived CD103+ dendritic cells carry antigen to the tumor-draining lymph node and are essential for CD8 T-cell priming**
Edward Roberts, University of California, San Francisco, CA

4:05 p.m.-4:35 p.m.
**Refreshment Break**
Lenox Ballroom, Empire Ballroom, and Metropolitan Ballroom Foyer

4:35 p.m.-6:35 p.m.
**Plenary Session 2: Tumor Antigens for Targeting: Insights from Genomics**
Metropolitan Ballroom
**Session Chairperson:** Christoph Huber, Johannes Gutenberg University Mainz Medical Center, Mainz, Germany

4:35 p.m.  **Chairperson perspective**
Christoph Huber

4:45 p.m.  **Personalizing cancer immunotherapy**
Robert D. Schreiber, Washington University School of Medicine, St. Louis, MO

5:15 p.m.  **Targeting the mutanome for individualized cancer immunotherapy**
Ugur Sahin, TRON Translational Cancer Center-Johannes Gutenberg University; BioNTech Biopharmaceutical New Technologies Corporation, Mainz, Germany

5:45 p.m.  **Impact of the immunogenic landscape of cancers on immunotherapy**
Hans-Georg Rammensee, University of Tuebingen, Tuebingen, Germany

6:15 p.m.  **Durable complete response in a patient with metastatic melanoma following adoptive transfer of autologous T cells recognizing 10 mutated tumor antigens**
Todd D. Prickett, National Cancer Institute, Bethesda, MD

6:45 p.m.-8:45 p.m.
**Reception**
Central Park and Lenox Ballroom

**Poster Session A**
Empire Ballroom

**Biomarkers**
**Clinical Trials of Cancer Immunotherapies**
**Drug Development**
Thursday, September 17, 2015

7:00 a.m.-8:00 a.m.
Continental Breakfast
Central Park, Lenox Ballroom, and New York Ballroom Foyer

7:45 a.m.-8:35 a.m.
The 2015 William B. Coley Lectures
Metropolitan Ballroom
7:45 a.m.  Alexander Rudensky, Memorial Sloan Kettering Cancer Center, New York, NY
8:10 a.m.  Glenn Dranoff, Novartis Institutes for BioMedical Research, Cambridge, MA

8:35 a.m.-12:05 p.m.
Plenary Session 3: Clinical Trials of Cancer Immunotherapies, Part 1
Metropolitan Ballroom
Session Chairperson: Glenn Dranoff, Novartis Institutes for BioMedical Research, Cambridge, MA
8:35 a.m.  Combination checkpoint blockade
Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center, Ludwig Cancer Research, New York, NY
9:05 a.m.  Treating the tumor and treating the host
Ronald Levy, Stanford University School of Medicine, Stanford, CA
9:35 a.m.  Designing immunostimulatory mAb to promote anticancer immunity
Martin J. Glennie, University of Southampton, Southampton, United Kingdom

10:05 a.m.  Refreshment Break
Central Park, Lenox Ballroom, and New York Ballroom Foyer

10:35 a.m.  Engineered T cells for cancer therapy
Carl H. June, Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA

11:05 a.m.  Engaging T cells against cancer: BLINCYTO* and beyond – the BiTE® platform
Dirk Nagorsen, Amgen, Inc., Thousand Oaks, CA (not eligible for CME credit)

11:35 a.m.  Combinatorial modalities with immune checkpoint blockade
F. Stephen Hodi, Dana-Farber Cancer Institute, Boston, MA

12:05 p.m.-1:35 p.m.
Lunch Session: Roundtable Discussion: The Regulatory Landscape for Cell and Gene Therapy
Metropolitan Ballroom
Session Chairperson: Cedrik Britten, GlaxoSmithKline, Stevenage, Hertfordshire, United Kingdom
Lunch will be served.
Discussants:
Gwendolyn Binder-Scholl, Adaptimmune LLC, Oxon, United Kingdom
Cedrik Britten
Elma Hawkins, Lion Biotechnology, New York, NY
Robert Hawkins, Cancer Research UK Manchester Institute, Manchester, United Kingdom
Thomas Hinz, Paul-Ehrlich-Institut, Langen, Germany
Laura Johnson, University of Pennsylvania, Philadelphia, PA
Cari June, Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA
Michael Kalos, Lilly, New York, NY
David Lebwohl, Novartis Pharmaceuticals Corporation, Florham Park, NJ
Celia Witten, Center for Biologics Evaluation and Research, FDA, Rockville, MD

*Proffered presentation
CONFERENCE PROGRAM AND SCHEDULE

12:05 p.m.-1:35 p.m.
Lunch
Central Park and Lenox Ballroom

1:45 p.m.-5:15 p.m.
Plenary Session 4: Tumor Microenvironment and the Cross Talk Between Immune/Inflammatory Cells and the Tumor Stroma, Matrix, and Vasculature
Metropolitan Ballroom
Session Chairperson to be announced

1:45 p.m.  Chairperson perspective
Speaker to be announced

1:55 p.m.  Inflammation and cancer: Immune cells as targets for anticancer therapy
Lisa Coussens, Oregon Health & Science University, Portland, OR

2:25 p.m.  Therapy-induced anticancer immunosurveillance: The example of successful chemotherapies
Guido Kroemer, Cordeliers Research Center (INSERM) - Institut Gustave-Roussy, Villejuif, France

2:55 p.m.  Tumor stroma: Immunomodulatory functions and a target of immunotherapy
Ellen Puré, University of Pennsylvania School of Veterinary Medicine, Philadelphia, PA

3:25 p.m.  Refreshment Break
Central Park, Lenox Ballroom, and New York Ballroom Foyer

3:55 p.m.  Regulation of T-cell homing in tumors
George Coukos, Ludwig Center for Cancer Research-University of Lausanne, Lausanne, Switzerland

4:25 p.m.  Cancer subtypes and their immune microenvironments
Wolf Herve Fridman, Cordeliers Research Center (INSERM), Paris, France

4:55 p.m.  Hypoxia is an essential driver of immune suppression in the tumor microenvironment*
Michael A. Curran, The University of Texas MD Anderson Cancer Center, Houston, TX

*Proffered presentation

Friday, September 18, 2015

7:00 a.m.-8:00 a.m.
Continental Breakfast
Central Park, Lenox Ballroom, and New York Ballroom Foyer

7:00 a.m.-8:00 a.m.
Meet the Editors
Central Park

Cancer Immunology, Immunotherapy
Graham P. Pawelec, Editor-in-Chief
Suzanne Ostrand-Rosenberg, Editor-in-Chief

Cancer Immunology Research
Robert D. Schreiber, Editor-in-Chief
Philip D. Greenberg, Editor-in-Chief
Linda J. Miller, Executive Editor

Oncoimmunology
Guido Kroemer, Editor-in-Chief
Laurence Zitvogel, Editor-in-Chief
Lorenzo Galluzzi, Editor-in-Chief

8:00 a.m.-9:40 a.m.
Plenary Session 5: Immunotherapy of Persistent Viral Infections and Virus-1 Induced Cancers
Metropolitan Ballroom

Session Chairperson: Cornelis J.M. Melief, Leiden University Medical Center and ISA Pharmaceuticals BV, Leiden, The Netherlands

8:00 a.m.  Chairperson perspective
Cornelis J.M. Melief

8:10 a.m.  Properly timed chemo-immunotherapy of cancer
Sjoerd Henricus van der Burg, Leiden University Medical Center, Leiden, The Netherlands

8:40 a.m.  Immunotherapy with virus-specific T cells
Helen Heslop, Baylor College of Medicine, Houston, TX

9:10 a.m.  T-cell memory and exhaustion
Rafi Ahmed, Emory University, Atlanta, GA

The Inaugural International Cancer Immunotherapy Conference
9:40 a.m.-10:10 a.m.  
Refreshment Break  
Metropolitan East and West Foyer

10:10 a.m.-12:40 p.m.  
Plenary Session 6: Biomarkers  
Metropolitan Ballroom

Session Chairperson: Ira Mellman, Genentech, Inc., South San Francisco, CA

10:10 a.m.  Chairperson perspective: Biomarkers and mechanism in immunotherapy  
Ira Mellman

10:40 a.m.  Immune checkpoint therapy: Immune monitoring on presurgical and tissue-based clinical trials  
Padmanee Sharma, The University of Texas MD Anderson Cancer Center, Houston, TX

11:10 a.m.  Antigenome and immune contexture in cancer  
Jerome Galon, INSERM, Paris, France

11:40 a.m.  Genomic assessment of tumor immune profiles  
Christian Ottensmeier, University of Southampton, Southampton, United Kingdom

12:10 p.m.  Tumor-expressed IDO recruits and activates MDSCs in a Treg-dependent manner  
Rikke B. Holmgaard, Memorial Sloan Kettering Cancer Center, Ludwig Cancer Research, New York, NY

12:40 p.m.-2:10 p.m.  
Lunch Session: Imaging and Targeting of the Antitumor Response  
Metropolitan Ballroom

2:25 p.m.-4:25 p.m.  
Concurrent Session 1: Microbiome  
Room TBD; see program addendum

Session Chairperson to be announced

2:25 p.m.  Chairperson perspective  
To be announced

2:35 p.m.  Gut microbiota regulates anticancer immune responses  
Laurence Zitvogel, Gustave Roussy Cancer Center, Villejuif, France

3:05 p.m.  Commensal microorganisms and polymorphic mucosal surfaces determine the evolution of distal metastatic tumors  
Jose R. Conejo-Garcia, The Wistar Institute, Philadelphia, PA

3:35 p.m.  Biofilms, genetics, and colon cancer  
Cynthia L. Sears, Johns Hopkins University, Baltimore, MD

4:05 p.m.  Tracking microbial sensing in colorectal cancer using bioorthogonal click chemistry*  
Jason Hudak, Harvard Medical School, Boston, MA

*Proffered presentation

1:45 p.m.  Imaging immunity: Creating a quantitative spatiotemporal understanding of host defense and antitumor responses  
Ronald N. Germain, National Institute of Allergy and Infectious Disease, NIH, Bethesda, MD

12:40 p.m.-2:10 p.m.  
Lunch  
Central Park and Lenox Ballroom

2:25 p.m.-4:25 p.m.  
Concurrent Session 1: Microbiome  
Room TBD; see program addendum

Session Chairperson to be announced

2:25 p.m.  Chairperson perspective  
To be announced

2:35 p.m.  Gut microbiota regulates anticancer immune responses  
Laurence Zitvogel, Gustave Roussy Cancer Center, Villejuif, France

3:05 p.m.  Commensal microorganisms and polymorphic mucosal surfaces determine the evolution of distal metastatic tumors  
Jose R. Conejo-Garcia, The Wistar Institute, Philadelphia, PA

3:35 p.m.  Biofilms, genetics, and colon cancer  
Cynthia L. Sears, Johns Hopkins University, Baltimore, MD

4:05 p.m.  Tracking microbial sensing in colorectal cancer using bioorthogonal click chemistry*  
Jason Hudak, Harvard Medical School, Boston, MA

*Proffered presentation
CONFERENCE PROGRAM AND SCHEDULE

2:25 p.m.-4:25 p.m.
Concurrent Session 2: Companion Diagnostics: Assay Harmonization
Room TBD; see program addendum

Session Chairperson: Axel Hoos, GlaxoSmithKline Pharmaceuticals, Collegeville, PA

2:25 p.m. Introduction
Axel Hoos

2:35 p.m. Abigail McElhinny, Ventana Medical Systems, Inc., Tucson, AZ

2:45 p.m. Robert A. Anders, Johns Hopkins University School of Medicine, Baltimore, MD

3:05 p.m. Paul Tumeh, UCLA Medical Center, Los Angeles, CA

3:25 p.m. Kenneth Bloom, GE Healthcare, Aliso Viejo, CA

3:45 p.m. Panel Discussion
Robert A. Anders
Kenneth Bloom
Axel Hoos
Ian McCaffery, Genentech, South San Francisco, CA
Abigail McElhinny
Jim Novotny, Bristol-Myers Squibb, Princeton, NJ
Reena Philip, Food and Drug Administration Center for Devices and Radiological Health, Silver Spring, MD
Dave Stanforth, Dako North America - Agilent Technologies, Carpinteria, CA
Paul Tumeh

4:45 p.m.-6:45 p.m.
Reception
Central Park and Lenox Ballroom

Poster Session B
Empire Ballroom

Companion Diagnostics: Assay Harmonization
Drug Development
Imaging and Targeting of the Antitumor Response
Immunotherapy of Persistent Viral Infections and Virus-1 Induced Cancers
Preclinical Models
Trials in Progress (promising ongoing trials or unique trial designs that have not yet yielded results)
Tumor Microenvironment and Cross Talk with the Immune System

Saturday, September 19, 2015

7:00 a.m.-8:00 a.m.
Continental Breakfast
Central Park, Lenox Ballroom, and New York Ballroom Foyer

8:00 a.m.-10:00 a.m.
Concurrent Session 3: Preclinical Models
Room TBD; see program addendum

Session Chairperson: Philip D. Greenberg, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA

8:00 a.m. Chairperson perspective
Philip D. Greenberg

8:10 a.m. Modeling combination immunotherapy studies on CNS melanoma
Charles G. Drake, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD

8:40 a.m. Designing combination immunotherapies to drive synergistic innate and adaptive antitumor immunity
Darrell J. Irvine, MIT Koch Institute for Integrative Cancer Research, Cambridge, MA

9:10 a.m. Engineered T-cell receptor-based therapy of pancreatic ductal adenocarcinoma
Ingunn M. Stromnes, Fred Hutchinson Cancer Research Institute, University of Washington, Seattle, WA

4:45 p.m.-6:45 p.m.
Reception
Central Park and Lenox Ballroom

Poster Session B
Empire Ballroom

Companion Diagnostics: Assay Harmonization
Drug Development
Imaging and Targeting of the Antitumor Response
Immunotherapy of Persistent Viral Infections and Virus-1 Induced Cancers
Preclinical Models
Trials in Progress (promising ongoing trials or unique trial designs that have not yet yielded results)
Tumor Microenvironment and Cross Talk with the Immune System

Saturday, September 19, 2015

7:00 a.m.-8:00 a.m.
Continental Breakfast
Central Park, Lenox Ballroom, and New York Ballroom Foyer

8:00 a.m.-10:00 a.m.
Concurrent Session 3: Preclinical Models
Room TBD; see program addendum

Session Chairperson: Philip D. Greenberg, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA

8:00 a.m. Chairperson perspective
Philip D. Greenberg

8:10 a.m. Modeling combination immunotherapy studies on CNS melanoma
Charles G. Drake, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD

8:40 a.m. Designing combination immunotherapies to drive synergistic innate and adaptive antitumor immunity
Darrell J. Irvine, MIT Koch Institute for Integrative Cancer Research, Cambridge, MA

9:10 a.m. Engineered T-cell receptor-based therapy of pancreatic ductal adenocarcinoma
Ingunn M. Stromnes, Fred Hutchinson Cancer Research Institute, University of Washington, Seattle, WA

*Proffered presentation

The Inaugural International Cancer Immunotherapy Conference
9:40 a.m.  TGF-beta1 primed myeloid derived suppressor cells decrease tumor growth and lose their ability to inhibit T-cell proliferation via iNOS downregulation*  
Padmini Jayaraman, Baylor College of Medicine, Houston, TX

8:00 a.m.-10:00 a.m.  
Concurrent Session 4: Drug Development: Immuno-Oncology Trial Design  
Room TBD; see program addendum  

Session Chairperson: Axel Hoos, GlaxoSmithKline Pharmaceuticals, Collegeville, PA

8:00 a.m.  PD-1 directed antibody: A broad-based antineoplastic therapy  
Roy Baynes, Merck Research Laboratories, Rahway, NJ

8:30 a.m.  Title to be announced  
Daniel S. Chen, Genentech, Inc., South San Francisco, CA

9:00 a.m.  Title to be announced  
Tai-Tsang Chen, Bristol-Myers Squibb, Wallingford, CT

9:30 a.m.  Title to be announced  
Axel Hoos

10:00 a.m.-10:30 a.m.  
Refreshment Break  
Central Park and Lenox Ballroom

10:30 a.m.-1:00 p.m.  
Plenary Session 7: Clinical Trials of Cancer Immunotherapies, Part 2  
Metropolitan Ballroom  

Session Chairperson: Robert H. Vonderheide, Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA

10:30 a.m.  Mechanisms of protective tumor immunity  
Glenn Dranoff, Novartis Institutes for BioMedical Research, Cambridge, MA

11:00 a.m.  Cancer prevention: Dendritic cell enhanced immune responses towards neoantigens in patients with Lynch syndrome  
Jolanda deVries, Centre for Molecular Life Sciences, Nijmegen, The Netherlands

11:30 a.m.  Prospect of a vaccine to prevent cancer in BRCA1-2 mutation carriers  
Robert H. Vonderheide

12:00 p.m.  Towards implementation of T-cell therapy in pancreatic cancer  
Rienk Offringa, Deutsches Krebsforschungszentrum, Heidelberg, Germany

12:30 p.m.  Nonviral gene transfer to redirect T-cell specificity  
Laurence J.N. Cooper, The University of Texas MD Anderson Cancer Center, Houston, TX

1:00 p.m.  Departure

*Proffered presentation